12:20 PM
Oct 10, 2018
 |  BC Extra  |  Company News

BARDA, J&J partner against chemical, biological and nuclear threats

HHS’s Biomedical Advanced Research and Development Authority partnered with Johnson & Johnson (NYSE:JNJ) to develop products to fight chemical, biological, radiation and nuclear threats, infectious diseases and antimicrobial resistant infections.

BARDA will initially provide more than $28 million over two years, and may provide up to $200 million over six years. The first compound under the project will target acute radiation syndrome and chemical threats. HHS said the product enhances survival and has shown beneficial effects on blood cells, which can be injured by radiation.

BARDA and J&J will have joint oversight, will cooperate to decide which projects to develop and keep in the portfolio, and will share development costs. The agreement also allows for BARDA and J&J to develop a portfolio of candidates for other disorders including trauma-induced bleeding, chemical and emerging threats, and bacterial infections.

In 2017, BARDA partnered with J&J’s Janssen Research & Development LLC unit to develop therapeutics to treat and prevent infectious diseases, including influenza. Under that agreement, BARDA may provide up to $273 million over five years, with an equal investment from Janssen.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD